Targeting TRPV1 for pain relief: limits, losers and laurels
- PMID: 22780443
- DOI: 10.1517/13543784.2012.704021
Targeting TRPV1 for pain relief: limits, losers and laurels
Abstract
Introduction: With 336 reviews, the capsaicin receptor TRPV1 arguably represent today's most extensively reviewed analgesic target. TRPV1 is strategically located at the peripheral terminals of primary sensory neurons where pain is generated. TRPV1 as a target for analgesic drugs has been validated in preclinical studies.
Areas covered: The therapeutic potential of targeting TRPV1 by agonists and antagonists for pain relief is discussed based on our experience and a critical review of the literature. Strategies to overcome adverse effects are explored.
Expert opinion: Since its discovery in 1997, TRPV1 has run the gamut from excitement to disappointment to cautious optimism. Topical capsaicin has been disappointing for pain relief. By contrast, intrathecal resiniferatoxin is currently undergoing clinical trials in patients with intractable cancer pain. Some of the small-molecule TRPV1 antagonists have successfully passed Phase I safety and tolerability studies in healthy volunteers into Phase II studies to access efficacy in patients. Others showed worrisome unforeseen adverse effects, most important, hyperthermia and impaired noxious heat sensation. We conclude that TRPV1 blockade and desensitization are two promising, complimentary approaches for pain relief. Despite the roadblocks, TRPV1 remains a powerful tool in pain research and a promising therapeutic target.
Similar articles
-
Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.Brain Res Rev. 2009 Apr;60(1):267-77. doi: 10.1016/j.brainresrev.2008.12.006. Epub 2008 Dec 25. Brain Res Rev. 2009. PMID: 19150372 Review.
-
Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?Clin J Pain. 2008 Feb;24(2):142-54. doi: 10.1097/AJP.0b013e318158ed9e. Clin J Pain. 2008. PMID: 18209521 Review.
-
Transient receptor potential vanilloid 1 as a therapeutic target in analgesia.Expert Opin Ther Targets. 2013 Jun;17(6):641-57. doi: 10.1517/14728222.2013.772580. Epub 2013 Feb 20. Expert Opin Ther Targets. 2013. PMID: 23421411 Review.
-
Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and N-oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat.Eur J Pain. 2010 May;14(5):480-6. doi: 10.1016/j.ejpain.2009.08.005. Epub 2009 Oct 1. Eur J Pain. 2010. PMID: 19800272
-
Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.Drug Discov Today. 2009 Jan;14(1-2):56-67. doi: 10.1016/j.drudis.2008.11.005. Epub 2008 Dec 26. Drug Discov Today. 2009. PMID: 19063991 Review.
Cited by
-
5-HT1D receptors inhibit the monosynaptic stretch reflex by modulating C-fiber activity.J Neurophysiol. 2019 May 1;121(5):1591-1608. doi: 10.1152/jn.00805.2018. Epub 2019 Jan 9. J Neurophysiol. 2019. PMID: 30625007 Free PMC article.
-
TRPV1: A Target for Rational Drug Design.Pharmaceuticals (Basel). 2016 Aug 23;9(3):52. doi: 10.3390/ph9030052. Pharmaceuticals (Basel). 2016. PMID: 27563913 Free PMC article. Review.
-
Discovery of N-(3-fluoro-4-methylsulfonamidomethylphenyl)urea as a potent TRPV1 antagonistic template.Bioorg Med Chem Lett. 2016 Aug 1;26(15):3603-7. doi: 10.1016/j.bmcl.2016.06.010. Epub 2016 Jun 7. Bioorg Med Chem Lett. 2016. PMID: 27317643 Free PMC article.
-
No requirement of TRPV1 in long-term potentiation or long-term depression in the anterior cingulate cortex.Mol Brain. 2014 Apr 5;7:27. doi: 10.1186/1756-6606-7-27. Mol Brain. 2014. PMID: 24708859 Free PMC article.
-
Capsaicinoids in the treatment of neuropathic pain: a review.Ther Adv Neurol Disord. 2014 Jan;7(1):22-32. doi: 10.1177/1756285613501576. Ther Adv Neurol Disord. 2014. PMID: 24409200 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
